Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Inventory (2023 - 2024)

Seres Therapeutics (MCRB) has disclosed Change in Inventory for 2 consecutive years, with $10.4 million as the latest value for Q3 2024.

  • Quarterly Change in Inventory fell 20.78% to $10.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Jun 2025, down 78.08% year-over-year, with the annual reading at $33.8 million for FY2024, 13.99% up from the prior year.
  • Change in Inventory hit $10.4 million in Q3 2024 for Seres Therapeutics, down from $11.0 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $13.2 million in Q3 2023 to a low of $5.3 million in Q2 2023.